Cargando…
Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice
Given the increase in bacterial resistance and the decrease in the development of new antibiotics, the appropriate use of old antimicrobials has become even more compulsory. Clindamycin is a lincosamide antibiotic approved for adults and children as a drug of choice for systemic treatment of staphyl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137603/ https://www.ncbi.nlm.nih.gov/pubmed/35625345 http://dx.doi.org/10.3390/antibiotics11050701 |
_version_ | 1784714418262638592 |
---|---|
author | Armengol Álvarez, Laura Van de Sijpe, Greet Desmet, Stefanie Metsemakers, Willem-Jan Spriet, Isabel Allegaert, Karel Rozenski, Jef |
author_facet | Armengol Álvarez, Laura Van de Sijpe, Greet Desmet, Stefanie Metsemakers, Willem-Jan Spriet, Isabel Allegaert, Karel Rozenski, Jef |
author_sort | Armengol Álvarez, Laura |
collection | PubMed |
description | Given the increase in bacterial resistance and the decrease in the development of new antibiotics, the appropriate use of old antimicrobials has become even more compulsory. Clindamycin is a lincosamide antibiotic approved for adults and children as a drug of choice for systemic treatment of staphylococcal, streptococcal, and gram-positive anaerobic bacterial infections. Because of its profile and high bioavailability, it is commonly used as part of an oral multimodal alternative for prolonged parenteral antibiotic regimens, e.g., to treat bone and joint or prosthesis-related infections. Clindamycin is also frequently used for (surgical) prophylaxis in the event of beta-lactam allergy. Special populations (pediatrics, pregnant women) have altered cytochrome P450 (CYP)3A4 activity. As clindamycin is metabolized by the CYP3A4/5 enzymes to bioactive N-demethyl and sulfoxide metabolites, knowledge of the potential relevance of the drug’s metabolites and disposition in special populations is of interest. Furthermore, drug–drug interactions derived from CYP3A4 inducers and inhibitors, and the data on the impact of the disease state on the CYP system, are still limited. This narrative review provides a detailed survey of the currently available literature on pharmacology and pharmacokinetics and identifies knowledge gaps (special patient population, drug–drug, and drug–disease interactions) to describe a research strategy for precision medicine. |
format | Online Article Text |
id | pubmed-9137603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91376032022-05-28 Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice Armengol Álvarez, Laura Van de Sijpe, Greet Desmet, Stefanie Metsemakers, Willem-Jan Spriet, Isabel Allegaert, Karel Rozenski, Jef Antibiotics (Basel) Review Given the increase in bacterial resistance and the decrease in the development of new antibiotics, the appropriate use of old antimicrobials has become even more compulsory. Clindamycin is a lincosamide antibiotic approved for adults and children as a drug of choice for systemic treatment of staphylococcal, streptococcal, and gram-positive anaerobic bacterial infections. Because of its profile and high bioavailability, it is commonly used as part of an oral multimodal alternative for prolonged parenteral antibiotic regimens, e.g., to treat bone and joint or prosthesis-related infections. Clindamycin is also frequently used for (surgical) prophylaxis in the event of beta-lactam allergy. Special populations (pediatrics, pregnant women) have altered cytochrome P450 (CYP)3A4 activity. As clindamycin is metabolized by the CYP3A4/5 enzymes to bioactive N-demethyl and sulfoxide metabolites, knowledge of the potential relevance of the drug’s metabolites and disposition in special populations is of interest. Furthermore, drug–drug interactions derived from CYP3A4 inducers and inhibitors, and the data on the impact of the disease state on the CYP system, are still limited. This narrative review provides a detailed survey of the currently available literature on pharmacology and pharmacokinetics and identifies knowledge gaps (special patient population, drug–drug, and drug–disease interactions) to describe a research strategy for precision medicine. MDPI 2022-05-21 /pmc/articles/PMC9137603/ /pubmed/35625345 http://dx.doi.org/10.3390/antibiotics11050701 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Armengol Álvarez, Laura Van de Sijpe, Greet Desmet, Stefanie Metsemakers, Willem-Jan Spriet, Isabel Allegaert, Karel Rozenski, Jef Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title | Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title_full | Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title_fullStr | Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title_full_unstemmed | Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title_short | Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice |
title_sort | ways to improve insights into clindamycin pharmacology and pharmacokinetics tailored to practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137603/ https://www.ncbi.nlm.nih.gov/pubmed/35625345 http://dx.doi.org/10.3390/antibiotics11050701 |
work_keys_str_mv | AT armengolalvarezlaura waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT vandesijpegreet waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT desmetstefanie waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT metsemakerswillemjan waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT sprietisabel waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT allegaertkarel waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice AT rozenskijef waystoimproveinsightsintoclindamycinpharmacologyandpharmacokineticstailoredtopractice |